Defence Therapeutics has started mRNA studies - results in 6 weeks

Canadian biotech company Defence Therapeutics has taken the next step on its journey to improve mRNA vaccines using its Accum technology. To this end, the Company has begun comparative studies pitting a "naked" mRNA vaccine against the combination of mRNA vaccine and Accum. In this article, we discuss how the Canadians are proceeding, why CEO Sébastien Plouffe is confident, and which USD 43 billion acquisition may also give hope to shareholders of Defence Therapeutics.

Den vollständigen Artikel lesen ...